Investment House LLC Sells 11,705 Shares of Pfizer Inc. (PFE)
Investment House LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 11.9% in the 3rd quarter, HoldingsChannel reports. The firm owned 86,628 shares of the biopharmaceutical company’s stock after selling 11,705 shares during the quarter. Investment House LLC’s holdings in Pfizer were worth $3,093,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of PFE. Shine Investment Advisory Services Inc. purchased a new stake in Pfizer during the 2nd quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware purchased a new stake in shares of Pfizer in the 2nd quarter valued at $103,000. D. Scott Neal Inc. boosted its holdings in shares of Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 504 shares during the last quarter. Herndon Capital Management LLC purchased a new stake in shares of Pfizer in the 2nd quarter valued at $120,000. Finally, Lipe & Dalton boosted its holdings in shares of Pfizer by 6.9% in the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after acquiring an additional 300 shares during the last quarter. Institutional investors and hedge funds own 69.74% of the company’s stock.
Shares of Pfizer Inc. (NYSE PFE) opened at $36.45 on Tuesday. The firm has a market cap of $217,270.00, a P/E ratio of 22.36, a P/E/G ratio of 2.46 and a beta of 1.01. Pfizer Inc. has a 1-year low of $30.90 and a 1-year high of $37.35. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be issued a $0.34 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. This represents a $1.36 annualized dividend and a yield of 3.73%. Pfizer’s dividend payout ratio (DPR) is 78.53%.
Pfizer declared that its Board of Directors has initiated a share repurchase program on Monday, December 18th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.
Several equities analysts recently issued reports on the stock. Morgan Stanley set a $41.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Friday. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Monday. Deutsche Bank set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $37.98 target price for the company in a research note on Monday. Finally, Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Buy” and a consensus price target of $38.83.
In other Pfizer news, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the sale, the insider now owns 117,432 shares of the company’s stock, valued at $4,145,349.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,450 shares of company stock worth $1,065,220. 0.06% of the stock is owned by corporate insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.